NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness (TRIOMPHE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04471909 |
|
Recruitment Status :
Recruiting
First Posted : July 15, 2020
Last Update Posted : December 15, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Aortic Dissection Aortic Aneurysm Intramural Hematoma Penetrating Aortic Ulcer | Device: NEXUS Aortic Stent Graft System | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch |
| Actual Study Start Date : | October 20, 2020 |
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | January 2027 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Chronic Dissection |
Device: NEXUS Aortic Stent Graft System
Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta. Ascending Stent Graft intended to be deployed in the Ascending Aorta. OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion. |
| Experimental: Aneurysm |
Device: NEXUS Aortic Stent Graft System
Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta. Ascending Stent Graft intended to be deployed in the Ascending Aorta. OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion. |
| Experimental: Penetrating Aortic Ulcer and/or Intramural Hematoma |
Device: NEXUS Aortic Stent Graft System
Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta. Ascending Stent Graft intended to be deployed in the Ascending Aorta. OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion. |
- Device Technical Failure [ Time Frame: 30 Days ]
- Failure to accurately deliver, track and deploy all required endovascular device components at the intended implantation site and failure to retrieve the device delivery systems without the need for unplanned additional procedures
- Device occlusion
- Failed exclusion of primary entry tear
- Additional unanticipated surgical or interventional procedure related to the device or procedure, to prevent life-threatening or permanent disabling event.
- Clinical Failure [ Time Frame: 30 Days ]Subjects experiencing early mortality or at least one of the following MAEs through 30-Day of Phase 1 Procedure and 30-Day of Index Procedure: Disabling stroke, permanent paralysis/paraplegia, renal failure, aortic rupture, development of new dissections in the thoracic aorta or brachiocephalic artery.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female age ≥ 18.
- Proximal/ascending native or previously implanted surgical graft landing zone of appropriate length
- Proximal/ascending native or previously implanted surgical graft landing zone of appropriate diameter
- Distal/descending native landing zone of appropriate length
- Distal/descending native landing zone of appropriate diameter
- Brachiocephalic trunk native landing zone of appropriate length
- Brachiocephalic trunk native landing zone of appropriate diameter
- Appropriate take off angle between the Brachiocephalic Artery and the Aortic Arch perpendicular
- Appropriate aortic arch perpendicular diameter
-
Chronic dissection with at least one of the following conditions:
- An aortic aneurysm with a maximum diameter ≥ 55 mm
- Rapidly expanding false lumen (growth of > 0.5 cm/6 months)
- Compressed true lumen associated with end organ malperfusion
- Symptomatic
-
Aneurysm with at least one of the following conditions:
- Dilatation of the aortic arch larger than 5 cm in diameter for subject with fusiform aneurysm
- Dilatation of the aortic arch is 1.5 times the normal diameter for subjects ascending or descending
- Dilation of the aortic arch larger than 2.5 cm for subject with saccular aneurysm
- Symptomatic aneurysm of the aortic arch
- Aortic diameter growth rate > 5mm per 6 months
- Postoperative pseudoaneurysm expanding from anastomotic suture lines
-
Penetrating aortic ulcer with at least one of the following:
- Symptomatic
- Ulcer demonstrates expansion
-
Intramural hematoma with at least one of the following:
- Symptomatic (persistent pain)
- Transverse or longitudinal expansion on serial imaging
- In the event of a lesion in the ascending aortic, the proximal/ascending native or previously implanted surgical graft the landing zone must be appropriate
- Femoral / iliac artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20 Fr. delivery catheter.
- Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA/MRA.
- Brachial/Axial Artery diameter that allows endovascular access suitable for 7 Fr.
- Subject is considered an appropriate candidate for an elective surgery.
- Subject is considered to be at high risk for open repair, as determined by the investigator.
- Access vessels, iliac/femoral & brachial/axillary compatible with vascular access techniques (femoral cutdown or percutaneous), devices, and /or accessories.
- Subject is willing and able to comply with procedures specified in the protocol and is able to return for follow-up visits as specified by the protocol.
Exclusion Criteria:
- Acute dissection
- Lesions that can be safely treated with TEVAR landing in zone 2 (with or w/o LSA vascularization)
- Required emergent treatment, e.g., trauma, rupture
- Acute vascular injury of the aorta due to trauma
- Aortic rupture or unstable aneurysm
- Received a previous stent or stent graft in the treated area (including planned landing area)
- Required surgical or endovascular treatment of an infra-renal aneurysm at time of implantation
- Planned major surgical or interventional procedure at time of screening, to be performed after the NEXUS™ implantation.
- Any major surgical or interventional procedure 6 weeks before the NEXUS™ implantation, exclusive of planned procedures that are needed for the safe and effective placement of the stent graft (e.g. supra-aortic bypass).
- Subject has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 90 days prior to the planned implantation
- Subjects with severe aortic valvular insufficiency as determined by echocardiography
- Mechanical valve that preclude safe delivery of NEXUS™
- Known Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes)
- Subject has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture
- Pregnant
- Life expectancy of less than 2 years
- Unsuitable vascular anatomy
- Subject who have a previously implanted surgical wrap of the ascending aorta
- Any medical condition that, according to the investigator's decision, might expose the subject to increased risk by the investigational device or procedure.
- An aneurysm that is mycotic, inflammatory or suspected to be infected.
- Subject with hostile groins/axilla (scarring, obesity, or previous failed puncture) unless conduit are used.
- Subjects with severe atherosclerosis, severe calcification or extensive intraluminal thrombus of the aorta or in the brachiocephalic trunk
- Subject is suffering from unstable angina or NYHA classification III and IV.
- Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.
- Subject with a contraindication to undergo angiography
- Subject with known sensitivities or allergies to the device materials (including Nitinol [NiTi], polyester fabric [PET], tantalum [TA])
- Clinical conditions that severely inhibit x-ray visualization of the Aorta.
- Subject has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator
- Acute renal failure; chronic renal failure (excluding dialysis); Creatinine > 2.00 mg/dl
- Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment.
- Active participation in another clinical study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints in this study, or subject is planning to participate in such study prior to the completion of this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04471909
| Contact: Jessica Kleine | (612)2800208 | j.Kleine@endospan.com | |
| Contact: Jennifer Miller | j.miller@endospan.com |
Show 30 study locations
| Responsible Party: | Endospan Ltd. |
| ClinicalTrials.gov Identifier: | NCT04471909 |
| Other Study ID Numbers: |
CIP-009 |
| First Posted: | July 15, 2020 Key Record Dates |
| Last Update Posted: | December 15, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
|
Aneurysm Aortic Aneurysm Aortic Dissection Penetrating Atherosclerotic Ulcer Hematoma Vascular Diseases Cardiovascular Diseases |
Aortic Diseases Hemorrhage Pathologic Processes Dissection, Blood Vessel Acute Aortic Syndrome Arteriosclerosis Arterial Occlusive Diseases |